Impact News +++ Google enters massive 3.6-GW power deal with Constellation Energy (Reuters EN) +++ CONSTELLATION ENERGY Aktie +3,21%

OCUGEN Aktie

>OCUGEN Aktienkurs

0.939 EUR +0.8% (TradegateBSX)

Ask: 0.944 EUR / 5000 Stück

Bid: 0.922 EUR / 5000 Stück

Tagesumsatz: 9268 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

OCUGEN Aktie über LYNX handeln

Intraday

1 Jahr

>OCUGEN Performance

1 Woche: +1,9%

1 Monat: -20,9%

3 Monate: -30,8%

6 Monate: -40,1%

1 Jahr: -38,6%

laufendes Jahr: -25,8%

>OCUGEN Aktie

Profil:

Ocugen Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for blindness diseases and other serious ocular conditions. Its current programs center on a modifier gene therapy platform designed to address in..
>Volltext..

Insiderhandel:

>OCUGEN Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>OCUGEN Peer Group

Gesundheit, Augenmedizin/ Sehhilfen, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika

>OCUGEN Chart & Kurs - NASDAQ

>OCUGEN News

06.10.26 - 13:03

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate (GlobeNewswire EN)

MALVERN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on developing and commercializing novel gene therapies to address blindness diseases, today announced the appointment of Jolanda Crombach, MSc PharmD, as General Manager of the Company's European affiliate. Ms. Crombach, an accomplished pharmaceutical executive with more than 20 years of industry experience, will lead the Company's newly established European affiliate, headquartered in Amsterdam, Netherlands....

30.09.26 - 13:03	Ocugen to Participate in Upcoming Scientific Conferences (GlobeNewswire EN)
	MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific conferences....

29.09.26 - 13:03	Ocugen to Participate in Upcoming October Investor and Industry Conferences (GlobeNewswire EN)
	MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of its executive leadership team will present at two upcoming investor and industry conferences....

25.09.26 - 13:03

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa (GlobeNewswire EN)

MALVERN, Pa., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that OCU400 has been granted provisional approval and priority designation from the LARTA Board, the regulatory agency responsible for reviewing and approving longevity and regenerative therapy programs within the Commonwealth of The Bahamas. Ocugen will supply OCU400 through an EAP, with the goal of treating the first RP patient within 90 days, following full LARTA approval....

12.09.26 - 07:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Ocugen im Wert von 589110 USD (Insiderkauf)
	Musunuri, Shankar - Vorstand - Tag der Transaktion: 2026-09-09...

09.09.26 - 18:54	Ocugen slips after interim trial data for Stargardt disease candidate (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.09.26 - 18:15	OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy (Zacks)
	Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028....

13.08.26 - 20:48	Ocugen (OCGN) Q2 2026 Earnings Call Transcript (Fool)
	Gene therapy developer advances three Phase III programs toward 2028 regulatory filings....

11.08.26 - 20:18	Ocugen präsentiert spätphasige Gentherapie-Strategie für Augenerkrankungen (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

07.08.26 - 20:30	Ocugen′s Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls (Zacks)
	OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028....

06.08.26 - 13:06	Ocugen Provides Business Update with Second Quarter 2026 Financial Results (GlobeNewswire EN)
	Conference Call and Webcast Today at 8:30 a.m. ET...

05.08.26 - 18:06	Ocugen Q2 2026 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.26 - 13:06	Ocugen to Participate in Upcoming August Investor Conferences (GlobeNewswire EN)
	MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor conferences in August 2026....

29.07.26 - 13:06

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire EN)

MALVERN, Pa, July 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to Ocugen's investigational product OCU410 for the treatment of geographic atrophy (GA), secondary to dry age-related macular degeneration (dAMD)....

28.07.26 - 22:06	Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results (GlobeNewswire EN)
	MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Thursday, August 6, 2026....

13.07.26 - 13:27	Ocugen signs OCU400 licensing term sheet (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.07.26 - 13:06

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa (GlobeNewswire EN)

MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region....

10.07.26 - 16:54	Ocugen treibt Gentherapie-Pipeline für Augenerkrankungen voran (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

01.07.26 - 13:03	Ocugen to Participate in Upcoming July Industry Conferences (GlobeNewswire EN)
	MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in July 2026....

18.06.26 - 03:01	Insiderhandel: Chief Financial Officer kauft Aktien von Ocugen im Wert von 25830 USD (Insiderkauf)
	Johnson-Greene, Treerita Essalima - Vorstand - Tag der Transaktion: 2026-06-15...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Philosophen verderben die Sprache, Poeten die Logik, und mit dem Menschenverstand kommt man durchs Leben nicht mehr. - Friedrich Johann Christoph Schiller

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram